GermanyPredicting potent drug combinations by exploiting monotherapy resistance

July 19, 2022by pcdata0

Dates: 01/01/2021
31/12/2025


Topic: Biomarkers identification
AI/Big data


Project type: Preclinic
Theranostic


Project target: Cancer


Financing:

H2020-EU.1.1. – EXCELLENT SCIENCE – European Research Council (ERC)


Participating agents:

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH


Keywords: Prostate cancer; colorectal cancer; drug resistance; reinforcement; tumour; biomarker; HTS; QSAR; monotherapy


Countries: Germany


Project page: Access page

 

Leave a Reply

Your email address will not be published. Required fields are marked *